

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	15 Day Supply Fiscal Edit
<b>First Implementation Date:</b>	February 16, 2005
<b>Proposed Date:</b>	December 17, 2020
<b>Prepared for:</b>	MO HealthNet
<b>Prepared by:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** To control expenditures on expensive drug therapies by setting a day supply limitation for newly initiated drug therapies

**Why Issue Selected:** Initiation of certain drug therapies can be costly to a prescription drug benefit program, especially when treatment failures occur due to side effects, a change in the patient's medical condition, and patient compliance. Limiting the supply of expensive medications on the initial prescription claim reduces the program cost for therapies that are discontinued or changed within the first few weeks of therapy. In most cases, new drug therapy failures are seen within the first two weeks of therapy initiation. By limiting the prescription supplies of newly prescribed products that are expensive and prone to treatment failure, MO HealthNet can reduce the cost associated with drug therapies that fail.

**Type of Criteria:**  Increased risk of ADE  Preferred Drug List  
 Appropriate Indications  Fiscal Edit

**Data Sources:**  Only Administrative Databases  Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: see Appendix A
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- Claim is for an agent screened by this edit – see Appendix A **AND**
- Claim has a calculated allowed amount less than \$150.00 **OR**
- Claim for ≤ 15 days supply **OR**
- Documented history of therapy with an agent in the same HICL as the incoming claim in the past year

## Denial Criteria

- Therapy will be denied if all approval criteria are not met

## Required Documentation

Laboratory Results:   
 MedWatch Form:

Progress Notes:   
 Other:

## Disposition of Edit

Denial: Exception code "0712" (Exceeds Initial Therapy Limitation)  
 Rule Type: PD

## Default Approval Period

1 year

## Appendix A – Agents Screened by the 15 Day Supply Fiscal Edit

DRUG DESCRIPTION – ATYPICAL ANTIPSYCHOTICS
ARIPRAZOLE (ABILIFY)
ASENAPINE (SAPHRIS)
BREXPIRAZOLE (REXULTI)
CARIPRAZINE (VRAYLAR)
CLOZAPINE (CLOZARIL)
ILOPERIDONE (FANAPT)
<b>LUMATEPERONE TOSYLATE (CAPLYTA)</b>
LURASIDONE (LATUDA)
OLANZAPINE (ZYPREXA/ZYPREXA IM)
OLANZAPINE/FLUOXETINE HCL (SYMBYAX)
PALIPERIDONE (INVEGA)
PIMAVANSERIN TARTRATE (NUPLAZID)
QUETIAPINE FUMARATE (SEROQUEL XR)
RISPERIDONE (RISPERDAL/RISPERDAL M)
RISPERIDONE MICROSPHERES (RISPERDAL CONSTA)
ZIPRASIDONE HCL (GEODON)
ZIPRASIDONE MESYLATE (GEODON INJECTION)
DRUG DESCRIPTION – ANTICONVULSANTS
BRIVARACETAM (BRIVIACT)
CARBAMAZEPINE (TEGRETOL/EPITOL/CARBATROL)
DIVALPROEX SODIUM (DEPAKOTE)
ESLICARBAZEPINE (APTIOM)
ETHOSUXIMIDE (ZARONTIN)
ETHOTOIN (PEGANONE)
EZOGABINE (POTIGA)
FELBAMATE (FELBATOL)
FOSPHENYTOIN SODIUM (CEREBYX)
GABAPENTIN (NEURONTIN)
LACOSAMIDE (VIMPAT)

SmartPA Fiscal Proposal Form  
 © 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and  
 Conduent Design™ are trademarks of Conduent Business Services, LLC in the  
 United States and/or other countries.

Other company trademarks are also acknowledged.

LAMOTRIGINE (LAMICTAL/LAMICTAL XR)
LEVETIRACETAM (KEPPRA)
METHSUXIMIDE (CELONTIN)
OXCARBAZEPINE (TRILEPTAL)
PERAMPANEL (FYCOMPA)
PHENYTOIN (DILANTIN)
PRIMIDONE (MYSOLINE)
RUFINAMIDE (BANZEL)
<b>STIRIPENTOL (DIACOMIT)</b>
TIAGABINE (GABATRIL)
TOPIRAMATE (QUDEXY XR/TOPAMAX)
VALPROATE SODIUM (DEPAKENE SYRUP)
VALPROIC ACID (DEPAKENE)
VIGABATRIN (SABRIL)
ZONISAMIDE (ZONEGRAN)
<b>DRUG DESCRIPTION – SEDATIVE HYPNOTICS</b>
REMELTEON (ROZEREM)

*SmartPA Fiscal Proposal Form*

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.